Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by JayjayUSA12007on May 13, 2018 10:21pm

141 Views

Post# 28024791

RE:Tesamorelin & treatment of HIV-associated lipodystry patents

While Tesamorelin (1st generation of GRF peptide) composition of matter patent is set to expired by 2020, Thera had another 2nd generation GRF peptide called TH1173 which is an improved version of tesamorelin. This patent will cover Tesamorelin 2nd generation well into 2030. So, even by 2020, someone might come up with a generic version of Tesamorelin, that generic version would not be able to compete with TH1173 2nd generation.

https://theratechnologies.s3.amazonaws.com/prod/media/th1173_us_patent_v_6_en.pdf

Bullboard Posts

Eminent acquires promising Nevada gold project